Susquehanna International Group, LLP Metacrine, Inc. Transaction History

Susquehanna International Group, LLP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.35 - $0.46 $8,935 - $11,743	-25,529 Reduced 51.48%	24,060 $10,000
Q3 2022 Nov 14, 2022	BUY	$0.43 - $0.55 $1,171 - $1,498	2,725 Added 5.81%	49,589 $24,000
Q2 2022 Aug 15, 2022	BUY	$0.36 - $0.63 $6,114 - $10,699	16,984 Added 56.84%	46,864 $23,000
Q1 2022 May 16, 2022	BUY	$0.43 - $0.7 $3,830 - $6,235	8,908 Added 42.48%	29,880 $18,000
Q4 2021 Feb 14, 2022	SELL	$0.64 - $3.83 $17,361 - $103,896	-27,127 Reduced 56.4%	20,972 $14,000
Q3 2021 Nov 15, 2021	BUY	$2.61 - $3.84 $125,538 - $184,700	48,099 New	48,099 $165,000
Q1 2021 May 17, 2021	SELL	$6.2 - $11.0 $199,968 - $354,783	-32,253 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$7.75 - $11.42 $249,960 - $368,329	32,253 New	32,253 $254,000

Ticker MTCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,569,500
Description
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.